Cross-sectional and longitudinal associations between insulin-like growth factor I and metabolic syndrome: A general population study in german adults

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 6, 2013, Pages 452-462

  Friedrich, Nele ^a   Nauck, Matthias ^a   Schipf, Sabine ^a   Völzke, Henry ^a   Brabant, Georg ^b   Wallaschofski, Henri ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

IGF I; IGFBP 3; Metabolic syndrome; Study of Health in Pomerania (SHIP); Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GERMANY; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

IGF-I; IGFBP-3; METABOLIC SYNDROME; STUDY OF HEALTH IN POMERANIA (SHIP); TYPE 2 DIABETES MELLITUS;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84883606835     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2412     Document Type: Article

References (49)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16(1): 3-34.
2. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest 1994; 93(3): 1131-1139.
3. Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 2008; 114(1): 17-22.
4. Russell-Jones DL, Bates AT, Umpleby AM, et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest 1995; 25(6): 403-411.
5. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317(3): 137-140.
6. Jorgensen JO, Moller L, Krag M, Billestrup N, Christiansen JS. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am 2007; 36(1): 75-87.
7. Norrelund H. The metabolic role of growth hormone in humans with particular reference to fasting. Growth Horm IGF Res 2005; 15(2): 95-122.
8. Saydah S, Ballard-Barbash R, Potischman N. Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes Control 2009; 20(8): 1309-1316.
9. Yeap BB, Chubb SA, Ho KK, et al. IGF1 And its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men. Eur J Endocrinol 2010; 162(2): 249-257.
10. Lam CS, Chen MH, Lacey SM, et al. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol 2010; 30(7): 1479-1484.
11. Oh J, Kim JY, Park S, et al. The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin. Clin Chim Acta 2012; 413(3-4): 506-510.
12. Brugts MP, van Duijn CM, Hofland LJ, Witteman JC, Lamberts SW, Janssen JA. Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes 2010; 59(2): 505-508.
13. Maggio M, Lauretani F, Ceda GP, et al. Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study. Am J Physiol Endocrinol Metab 2007; 292(1): E353-E358.
14. Friedrich N, Thuesen B, Jorgensen T, et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35(4): 768-773.
15. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359(9319): 1740-1745.
16. Wallander M, Brismar K, Ohrvik J, Ryden L, Norhammar A. Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia 2006; 49(10): 2247-2255.
17. Schneider HJ, Friedrich N, Klotsche J, et al. Prediction of incident diabetes mellitus by baseline IGF1 levels. Eur J Endocrinol 2011; 164(2): 223-229.
18. John U, Greiner B, Hensel E, et al. Study of Health in Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed 2001; 46(3): 186-194.
19. Alte D, Luedemann J, Rose HJ, John U. Laboratory markers carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcohol Clin Exp Res 2004; 28(6): 931-940.
20. NCEP. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-3421.
21. IDF. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2005.
22. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-2752.
23. Nauck M, Winkler K, Marz W, Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995; 41(12 Pt 1): 1761-1767.
24. Stone C, Koo CY. Additive Splines in Statistics. American Statistcal Association: Washington, DC, 1985.
25. Deutsche. Liga zur Bekämpfung des hohen Blutdruckes e.V 1999 Empfehlungen zur Hochdruckbehandlung (Recommendation for the treatment of hypertension). (15th edn). Heidelberg.
26. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clin Sci (Lond) 2009; 116(6): 507-512.
27. Wabitsch M, Heinze E, Debatin KM, Blum WF. IGF-I- and IGFBP-3-expression in cultured human preadipocytes and adipocytes. Horm Metab Res 2000; 32(11-12): 555-559.
28. Cousin SP, Hugl SR, Wrede CE, Kajio H, Myers MG Jr, Rhodes CJ. Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1. Endocrinology 2001; 142(1): 229-240.
29. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143(2): 339-342.
30. Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 2007; 24(9): 934-945.
31. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994; 41(1): 85-93.
32. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002; 175(1): 19-31.
33. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 1994; 94(3): 1126-1133.
34. Muzumdar RH, Ma X, Fishman S, et al. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes 2006; 55(10): 2788-2796.
35. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010; 19(9): 2298-2306.
36. Kalmijn S, Janssen JA, Pols HA, Lamberts SW, Breteler MM. A prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderly. J Clin Endocrinol Metab 2000; 85(12): 4551-4555.
37. Duggan C, Wang CY, Neuhouser ML, et al. Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer 2013; 132(5): 1191-1200.
38. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract 2011; 17(Suppl 4): 1-44.
39. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(6): 1587-1609.
40. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011; 57(4): 555-559.
41. Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol 1991; 260(6 Pt 1): E846-E851.
42. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79(3): 872-878.
43. Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992; 74(6): 1355-1360.
44. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metabolism 1995; 44(10 Suppl 4): 37-44.
45. Nam SY, Lee EJ, Kim KR, et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997; 21(5): 355-359.
46. Rasmussen MH, Frystyk J, Andersen T, Breum L, Christiansen JS, Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism 1994; 43(3): 315-319.
47. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000; 23(4): 465-471.
48. Moller N, Gjedsted J, Gormsen L, Fuglsang J, Djurhuus C. Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res 2003; 13(Suppl A): S18-S21.
49. Rajkumar K, Modric T, Murphy LJ. Impaired adipogenesis in insulin-like growth factor binding protein-1 transgenic mice. J Endocrinol 1999; 162(3): 457-465.